Senti Biosciences, Inc. entered into Securities Purchase Agreement with an entity affiliated with Celadon Partners SPV 24 valued at $40.0 million (effective 2026-04-27).
“On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.”
Debt Financings
Senti Biosciences, Inc. incurred convertible notes of $10.0 million with Celadon Partners SPV 24 affiliate at will not bear any interest unless an event of default has occurred maturing six months after the closing date of the Initial Notes.
“the first tranche consists of $10.0 million in aggregate principal amount of Notes that are to be issued (the “Initial Notes”), subject to the satisfaction of certain specified closing conditions”
Governance Changes
Senti Biosciences, Inc.: Upon consummation of the Reorganization, Senti Biosciences amended and restated its bylaws to simplify them after becoming a wholly-owned subsidiary (effective 2026-04-24).
“Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.”
Governance Changes
Senti Biosciences, Inc.: Upon consummation of the Reorganization, Senti Holdings adopted an Amended and Restated Certificate of Incorporation, and Senti Biosciences adopted a Third Amended and Restated Charter to simplify its certificate of incorporation after becoming a wholly-owned subsidiary (effective 2026-04-24).
“Upon consummation of the Reorganization, the Amended and Restated Certificate of Incorporation of Senti Biosciences Holdings (the “Amended and Restated Certificate of Incorporation”) and the Amended and Restated Bylaws of Senti Biosciences Holdings (the “Amended and Restated Bylaws”) are the same as the second amended and restated certificate of incorporation and amended and restated bylaws of Senti Biosciences in effect immediately prior to consummation of the Reorganization, respectively, other than changes permitted by Section 251(g) of the DGCL.”
Material Agreements
Senti Biosciences, Inc. amended A&R New Enterprise Designation Agreement with New Enterprise Associates 15, L.P. (effective 2026-04-24).
“Senti Biosciences amended and restated that certain Designation Agreement by and between Senti Biosciences and New Enterprise Associates 15, L.P. (“New Enterprise”), dated December 2, 2024 (as amended and restated, the “A&R New Enterprise Designation Agreement”)”
Material Agreements
Senti Biosciences, Inc. amended A&R Celadon Designation Agreement with Celadon Partners SPV 24 (effective 2026-04-24).
“Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)”
Material Agreements
Senti Biosciences, Inc. entered into Assignment and Assumption Agreement with Senti Biosciences Holdings (effective 2026-04-24).
“per share (“Senti Biosciences Holdings Common Stock”), issued in connection with the Merger are deemed registered under Section 12(b) of the Exchange Act as the common stock of the successor issuer.”
Material Agreements
Senti Biosciences, Inc. entered into Agreement and Plan of Merger with Merger Sub (effective 2026-04-24).
“On April 24, 2026, Senti Biosciences completed the Reorganization by implementing the Merger pursuant to the terms of the Merger Agreement.”
Earnings Releases
Senti Biosciences, Inc. reported the year ended December 31, 2025 results: net income Net loss ... for the full-year 2025 was $61.4 million, or $2.73 per share, EPS $2.73 per share.
“Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results”
Material Agreements
Senti Biosciences, Inc. entered into Letter Agreement with GeneFab, LLC valued at outstanding base rent of $1,374,005 may be satisfied via cash prepayment credit for work or services (effective 2025-09-01).
“On March 17, 2026, the Company entered into a letter agreement with GeneFab (the “Letter Agreement”), effective as of the Effective Date. The Letter Agreement provides, among other things, that the outstanding base rent of $1,374,005 owed by GeneFab to the Company may be satisfied, in whole or in part, through a cash prepayment credit to be applied toward work or services to be performed by GeneFab for the Company under a separate arrangement, that the Company may access such prepayment credit as of the Effective Date and that any unpaid portion must be paid in immediately available funds by September 1, 2026.”
Material Agreements
Senti Biosciences, Inc. amended First Amendment to Landlord's Consent to Sublease with 1430 South Loop Owner, LLC and GeneFab, LLC valued at Landlord consented to Sublease Amendment in consideration for $1.0 million Reduction Fee (effective 2025-09-01).
“On March 17, 2026, the Company entered into a First Amendment to Landlord’s Consent to Sublease (the “Consent Amendment”) among the Company, the Landlord and GeneFab, which was effective as of the Effective Date. Pursuant to the Consent Amendment, the Landlord consented to the Sublease Amendment in consideration for the payment by the Company or GeneFab of $1.0 million to the Landlord (the “Reduction Fee”).”
Material Agreements
Senti Biosciences, Inc. amended First Amendment to Sublease with GeneFab, LLC valued at subleased premises reduced to ~45,955 rentable square feet; base rent, operating expenses, taxes and (effective 2025-09-01).
“On March 17, 2026, the Company entered into a First Amendment to Sublease (the “Sublease Amendment”), which amended and restated that certain Sublease Agreement dated August 7, 2023 (the “Original Sublease Agreement” and the Original Sublease Agreement as amended by the Sublease Amendment, the “Amended Sublease”) by and between the Company, as sublandlord, and GeneFab, LLC (“GeneFab”) as subtenant. Pursuant to the Sublease Amendment, which was effective as of the Effective Date, the subleased premises were reduced to approximately 45,955 rentable square feet as of the Effective Date.”
Material Agreements
Senti Biosciences, Inc. amended First Amendment to Lease with 1430 South Loop Owner, LLC valued at reduction of leased premises from ~91,910 to ~45,955 rentable square feet; monthly base rent reduced (effective 2025-09-01).
“On March 17, 2026, Senti Biosciences, Inc. (the “Company”) entered into a First Amendment to Lease (the “Lease Amendment”), which amended that certain Research and Development and Laboratory Lease Agreement dated June 3, 2021 (the “Original Lease Agreement” and the Original Lease Agreement as amended by the Lease Amendment, the “Amended Lease”) by and between the Company and 1430 South Loop Owner, LLC (the “Landlord”) for the Company’s premises located at 1430 Harbor Bay Parkway, Alameda, California. Pursuant to the Lease Amendment, which is effective as of September 1, 2025 (the “Effective Date”), the Company has agreed to a reduction of the leased premises from approximately 91,910 rentable square feet to approximately 45,955 rentable square feet as of the Effective Date.”
Feng Hsiung was appointed as Class III Director at Senti Biosciences, Inc..
“On March 7, 2025, the Board of Directors (the “Board”) of Senti Biosciences, Inc. (the “Company”) approved the appointment of Feng Hsiung to the Board, pursuant to the terms of a letter agreement dated as of December 2, 2024, by and between the Company and Celadon Partners SPV 24.”
Jay Cross was appointed as Chief Financial Officer at Senti Biosciences, Inc..
“Jay Cross was appointed as the Company’s Chief Financial Officer, effective as of March 3, 2025.”
Yvonne Li departed as Interim Chief Financial Officer at Senti Biosciences, Inc..
“On January 31, 2025, Yvonne Li, the Consulting Agreement by and between Senti Biosciences, Inc. (the “Company”) and Yvonne Li, the Company’s Interim Chief Financial Officer, expired in accordance with its terms.”
Frances D. Schulz was appointed as Director at Senti Biosciences, Inc..
“On December 2, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board unanimously appointed Frances D. Schulz to fill a newly created vacancy on the Board resulting from the resignation of Dr. Farokhzad, such appointment to be effective upon the initial closing of the Offering.”
Omid Farokhzad resigned as Director at Senti Biosciences, Inc..
“On November 25, 2024, Omid Farokhzad, M.D., a member of the Board and the Audit Committee of the Board, notified the Board of his resignation as a director of the Company and all committees thereof, effective November 25, 2024.”
Kanya Rajangam was appointed as President at Senti Biosciences, Inc..
“Kanya Rajangam, M.D., Ph.D., the Company's Head of Research and Development, and Chief Medical Officer, was appointed to serve as the President of the Company, effective as of May 14, 2024”
Timothy Lu changed role as President at Senti Biosciences, Inc..
“Timothy Lu, M.D., Ph.D., Chief Executive Officer and President, stepped down as President”
Earnings Releases
Senti Biosciences, Inc. reported first quarter of 2024 results: net income Net loss was $12.1 million, or $0.26 per basic and diluted share, EPS $0.26 per basic and diluted share.
“Senti Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Yvonne Li was appointed as Interim Chief Financial Officer at Senti Biosciences, Inc..
“Yvonne Li was appointed as Interim Chief Financial Officer and will assume the duties of the Chief Financial Officer, effective May 4, 2024”
Timothy Lu was appointed as interim principal financial officer and principal accounting officer at Senti Biosciences, Inc..
“Timothy Lu, M.D., Ph.D., the Chief Executive Officer and President of the Company, was appointed to serve as the interim principal financial officer and principal accounting officer of the Company, effective as of May 4, 2024”
Deborah Knobelman resigned as Chief Financial Officer, Treasurer and Head of Corporate Development at Senti Biosciences, Inc..
“On April 23, 2024, Deborah Knobelman, Ph.D., the Chief Financial Officer, Treasurer and Head of Corporate Development of Senti Biosciences Inc. (“the Company”) and its principal financial officer and principal accounting officer, notified the Company of her decision to resign from her employment with the Company, effective May 3, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.